Tucidinostat
Tucidinostat (also known as Chidamide) is a histone deacetylase inhibitor (HDACi) used in the treatment of various types of cancer. It is particularly noted for its application in the treatment of peripheral T-cell lymphoma (PTCL) and breast cancer. Tucidinostat is an orally bioavailable, selective inhibitor of histone deacetylase (HDAC) subtypes 1, 2, 3, and 10.
Mechanism of Action[edit | edit source]
Tucidinostat works by inhibiting the activity of histone deacetylases, which are enzymes involved in the removal of acetyl groups from histone proteins. This inhibition leads to an accumulation of acetylated histones, resulting in a more relaxed chromatin structure and increased transcriptional activity of certain genes. The reactivation of these genes can induce cell cycle arrest, differentiation, and apoptosis in cancer cells.
Clinical Applications[edit | edit source]
Peripheral T-cell Lymphoma[edit | edit source]
Tucidinostat has been approved for the treatment of peripheral T-cell lymphoma (PTCL) in several countries. PTCL is a group of aggressive non-Hodgkin lymphomas that originate from mature T-cells and natural killer (NK) cells. The drug has shown efficacy in patients who have relapsed or are refractory to conventional chemotherapy.
Breast Cancer[edit | edit source]
In addition to its use in PTCL, Tucidinostat is being investigated for its potential in treating breast cancer. Studies have shown that it can enhance the sensitivity of cancer cells to other therapeutic agents, making it a promising candidate for combination therapy.
Side Effects[edit | edit source]
Common side effects of Tucidinostat include fatigue, nausea, vomiting, anemia, and thrombocytopenia. Patients undergoing treatment with Tucidinostat require regular monitoring of blood counts and liver function tests.
Research and Development[edit | edit source]
Tucidinostat is currently under investigation in various clinical trials for its efficacy and safety in treating other types of cancer, including non-small cell lung cancer (NSCLC) and colorectal cancer. Researchers are also exploring its potential in combination with other therapeutic agents to enhance its anticancer effects.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
